PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Prelude Therapeutics Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.39+0.13 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Prelude Therapeutics has not reported a dividend
No dividend per share appears in Prelude Therapeutics's annual filings since fiscal 2018.